GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » Beneish M-Score

Elanco Animal Health (Elanco Animal Health) Beneish M-Score

: -2.59 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Elanco Animal Health's Beneish M-Score or its related term are showing as below:

ELAN' s Beneish M-Score Range Over the Past 10 Years
Min: -3.45   Med: -2.59   Max: -2.22
Current: -2.59

During the past 9 years, the highest Beneish M-Score of Elanco Animal Health was -2.22. The lowest was -3.45. And the median was -2.59.


Elanco Animal Health Beneish M-Score Historical Data

The historical data trend for Elanco Animal Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -2.35 -2.59 -2.61 -2.59

Elanco Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.49 -2.41 -2.44 -2.59

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elanco Animal Health Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Elanco Animal Health's Beneish M-Score falls into.



Elanco Animal Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Elanco Animal Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0068+0.528 * 1.0064+0.404 * 0.9551+0.892 * 1.0011+0.115 * 1.0055
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0139+4.679 * -0.017964-0.327 * 1.0525
=-2.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $1,010 Mil.
Revenue was 1035 + 1068 + 1057 + 1257 = $4,417 Mil.
Gross Profit was 519 + 581 + 623 + 763 = $2,486 Mil.
Total Current Assets was $3,407 Mil.
Total Assets was $14,362 Mil.
Property, Plant and Equipment(Net PPE) was $1,026 Mil.
Depreciation, Depletion and Amortization(DDA) was $694 Mil.
Selling, General, & Admin. Expense(SGA) was $1,285 Mil.
Total Current Liabilities was $1,241 Mil.
Long-Term Debt & Capital Lease Obligation was $5,736 Mil.
Net Income was -141 + -1096 + -97 + 103 = $-1,231 Mil.
Non Operating Income was -70 + -1067 + -58 + -49 = $-1,244 Mil.
Cash Flow from Operations was 157 + 198 + 61 + -145 = $271 Mil.
Total Receivables was $1,002 Mil.
Revenue was 985 + 1026 + 1175 + 1226 = $4,412 Mil.
Gross Profit was 537 + 554 + 691 + 717 = $2,499 Mil.
Total Current Assets was $3,279 Mil.
Total Assets was $15,491 Mil.
Property, Plant and Equipment(Net PPE) was $999 Mil.
Depreciation, Depletion and Amortization(DDA) was $682 Mil.
Selling, General, & Admin. Expense(SGA) was $1,266 Mil.
Total Current Liabilities was $1,702 Mil.
Long-Term Debt & Capital Lease Obligation was $5,448 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1010 / 4417) / (1002 / 4412)
=0.228662 / 0.227108
=1.0068

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2499 / 4412) / (2486 / 4417)
=0.56641 / 0.562825
=1.0064

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3407 + 1026) / 14362) / (1 - (3279 + 999) / 15491)
=0.691338 / 0.72384
=0.9551

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4417 / 4412
=1.0011

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(682 / (682 + 999)) / (694 / (694 + 1026))
=0.405711 / 0.403488
=1.0055

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1285 / 4417) / (1266 / 4412)
=0.290921 / 0.286945
=1.0139

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5736 + 1241) / 14362) / ((5448 + 1702) / 15491)
=0.485796 / 0.461558
=1.0525

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1231 - -1244 - 271) / 14362
=-0.017964

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Elanco Animal Health has a M-score of -2.59 suggests that the company is unlikely to be a manipulator.


Elanco Animal Health Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanco Animal Health (Elanco Animal Health) Business Description

Traded in Other Exchanges
Address
2500 Innovation Way, Greenfield, IN, USA, 46140
Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Executives
Grace Mcardle officer: EVP, MANUFACTURING AND QUALITY 2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington officer: See remarks C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover director C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons director, officer: Pres., Chief Executive Officer 2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey director
Rajeev A. Modi officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen director C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De officer: See Remarks 2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger officer: Ex VP, Gen Counsel & Corp Sec C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia director 11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle director
Uncas Gp Llc director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson director 250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019